Get the Stockscreener App
63.67
5.12%
3.10
After Hours:
63.70
0.03
+0.05%
Moderna Inc stock is traded at $63.67, with a volume of 6.57M.
It is up +5.12% in the last 24 hours and down -6.74% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$60.57
Open:
$60.58
24h Volume:
6.57M
Relative Volume:
0.91
Market Cap:
$25.42B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-7.8159
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+13.18%
1M Performance:
-6.74%
6M Performance:
+58.74%
1Y Performance:
+148.13%
1-Day Range:
$59.29
$64.26
1-Week Range:
$53.71
$64.26
52-Week Range:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
63.67 | 24.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
525.73 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.99 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.00 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.26 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.05 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Capital World Investors reports 5.6% Moderna (MRNA) stake in Schedule 13G filing - Stock Titan
Bank of America Corp DE Sells 388,494 Shares of Moderna, Inc. $MRNA - MarketBeat
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? - Yahoo Finance
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market - Yahoo Finance
RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers - Yahoo Finance
FDA Approves New Flu Shot Using COVID-Era Tech—Here’s Who Can Get It - Newsweek
1st mRNA flu vaccine gets FDA nod after rare U-turn. What the technology does & why it faced scrutiny - ThePrint
Moderna, Inc. (MRNA) Stock Analysis: Navigating Potential Amidst A -14.07% Downside - DirectorsTalk Interviews
Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc. - MarketBeat
Watch RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers - Bloomberg.com
Moderna | History, Innovation, Challenges, & Facts - Encyclopedia Britannica
Moderna, Inc. $MRNA Shares Acquired by Empowered Funds LLC - MarketBeat
Moderna jumps as FDA flu-shot approval reinforces recent business momentum - Quiver Quantitative
FAQ: What mFLUSIVA's Approval May Signal for the Future of mRNA Vaccine Development - BioPharm International
Rule 10b5-1 plan drives Moderna, Inc. (NASDAQ: MRNA) CEO stock sales - Stock Titan
Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations - Pharmaceutical Technology
Moderna (MRNA) Wins FDA Flu Vaccine Approval On Questions Over Whether The Stock Is Fully Valued - simplywall.st
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones - Yahoo Finance
Moderna Inc (MRNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Moderna Inc (MRNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off - Yahoo Finance
What Moderna is and how it built its mRNA vaccine platform - qz.com
FDA Approves New, More Effective Flu Vaccine From Moderna - People.com
Expert available: FDA approves 1st mRNA flu shot, from Moderna | Newswise - Newswise
Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain - MedCity News
Opinion | The FDA, Replimune and a New Flu Shot - WSJ
FDA approves Moderna’s mFlu vaccine for adults 50 and older - CBS News
Here’s what the first mRNA flu vaccine could mean for flu season - Science News
The flu shot finally gets an upgrade - vox.com
Moderna Stock Flashing Intriguing ‘Buy The Dip’ Signal - Forbes
Moderna shares slide despite mFlusiva success 📉 What's next for the mRNA vaccines market giant? - XTB.com
MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine - Yahoo Finance
FDA approved Moderna's mRNA flu vaccine after initially refusing to review it - qz.com
Moderna wins FDA approval for first mRNA-based flu shot - americanbazaaronline.com
Moderna Just Got FDA Clearance for Flu Vaccine. The Stock Is Sliding. - Barron's
FDA approves Moderna mRNA flu shot - CNBC
FDA Approves mFLUSIVA, First mRNA-Based Flu Vaccine - Drug Topics
Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine - Benzinga
Moderna’s First mRNA Flu Shot Just Won FDA Approval. Now Researchers See Potential for HIV and Malaria - inc.com
Moderna's flu shot wins FDA approval after initial regulatory battle - The Business Journals
Piper Sandler reiterates Moderna stock rating on flu vaccine approval - Investing.com
The mRNA technology behind Moderna’s Covid vaccine reaches the flu - The Guardian
FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review - WSJ
Moderna’s mRNA Flu Shot Wins US Approval in FDA Turnaround - Bloomberg.com
FDA approves Moderna’s mRNA flu vaccine - Healthcare Dive
Moderna Stock Climbs on Flu Vaccine Approval - Schaeffer's Investment Research
U.S. approves Moderna’s mRNA vaccine for flu—the first of its kind - Scientific American
U.S. FDA approves first mRNA flu shot from Moderna - CNBC
Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock - BioSpace
FDA approves first mRNA flu vaccine - The Hill
Edgestream Partners L.P. Sells 28,698 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.58%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):